Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$200.37 USD

200.37
2,035,608

-3.18 (-1.56%)

Updated Nov 4, 2024 03:55 PM ET

After-Market: $200.23 -0.14 (-0.07%) 4:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

Kinjel Shah headshot

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.

Company News for Jul 26, 2024

Companies In The News Are: ABBV, VLO, NOC, LUV.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

Smart Beta ETF report for FVD

Q2 Earnings in Full Swing This week

Q2 Earnings in Full Swing This week.

Mark Vickery headshot

First Full Week of Q2 Earnings, PCE Out Friday

No fewer than 845 companies are scheduled to report this week, including Alphabet (GOOGL) and Tesla (TSLA) Tuesday.

Sundeep Ganoria  headshot

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.